Medical/Pharmaceuticals
Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer
SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-12-11 09:02
7916
Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
SHANGHAI and HONG KONG, Dec. 11, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...
2020-12-11 08:00
5331
European Union Intellectual Property Office Revokes Counterfeiter's Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed's falsely registered AQUAGOLD® design, originally created and owned by Aquavit. ...
2020-12-11 03:10
3578
Global Biosimilars Market Poised to Grow at Chart-topping Levels with a CAGR of 17.3%, Reaching $79.2 Billion by 2026
With the third wave of biosimilars in the spotlight during the forecast period, revenues from the sensory organs market will dominate growth, finds Frost & Sullivan SANTA CLARA, Calif., Dec. 11, 2020 /PRNewswire/ -- Frost & Sullivan's recent analysis,Access to New Therapy Areas to Drive Major Gr...
2020-12-11 03:00
1845
DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor and positive impact of reference anti-HER2 treatment on overall survival
Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 10, 2020...
2020-12-10 22:19
5005
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("...
2020-12-10 21:00
6234
MicroPort CRM initiates a clinical trial for breakthrough innovative left ventricular lead Axone(TM)
PARIS, Dec. 10, 2020 /PRNewswire/ -- MicroPort Cardio Rhythm Management (CRM) has announced the first enrollment in the Astral-4LV clinical trial[1] to evaluate the safety and efficiency of Axone™, a breakthrough innovative quadripolar left ventricular lead. Axone™ is designed for use in heart fa...
2020-12-10 19:23
1601
ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System
PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ -- ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise™ Ultrasound Renal Denervation System (the "Paradise System") demonstrated positive results in the RADIANCE-HTN TRIO ("TRIO") study...
2020-12-10 16:01
1715
InDevR Expands Commercial Portfolio for Coronavirus Vaccine Characterization
BOULDER, Colo., Dec. 10, 2020 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Spike Protein Kit and SARS-CoV-2 Spike ...
2020-12-10 15:00
1338
Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world
Gates Foundation pledges additional $250 million to accelerate development and equitable distribution of COVID-19 tests, treatments, and vaccines to end the pandemic SEATTLE, Dec. 10, 2020 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced it will commit an additional$250 millio...
2020-12-10 13:01
2932
Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%
SHANGHAI, Dec. 10, 2020 /PRNewswire/ -- On December 9, 2020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the ...
2020-12-10 12:14
3193
Cybernet on the Front Lines of Massive Vaccination Program
IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ -- All eyes are on the United Kingdom today as they are the first western country in the world to begin to issue COVID-19 vaccinations. This ambitious undertaking, which has been dubbed the largest mass-vaccination program in the country's history, will ...
2020-12-10 10:43
2154
Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced updates on the clinical devel...
2020-12-10 09:03
2699
CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("CStone", HKEX: 2616), Blueprint Medicines, announced on December 1st that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of patients with RET-altered thyroid can...
2020-12-10 08:30
5177
New Global Pooled Analysis Supports Clinical Utility of Circulating Tumor Cell Count for Early Monitoring of Metastatic Breast Cancer
Robust pooled analysis demonstrating how CTC count may help to optimize
treatment choices
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 10, 2020 /PRNewswire/ --
Menarini Silicon Biosystems
2020-12-10 01:59
2726
PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
DAEJEON, South Korea, Dec. 9, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of oli...
2020-12-09 23:00
1813
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium - RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negativ...
2020-12-09 22:00
3150
Sirtex Medical announces strategic investment in BlackSwan Vascular, Inc.
WOBURN, Mass., Dec. 9, 2020 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced a strategic investment in BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular emboliza...
2020-12-09 22:00
1545
Northway Biotechpharma, Biologics CDMO, Announces Company Brand Name Change to Northway Biotech
VILNIUS, Lithuania and WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Northway Biotechpharma, providing end-to-end contract drug development and manufacturing (CDMO) services, announces brand name change toNorthway Biotech. Along with the tradename change, Dr. Vladas Algirdas Bumelis also returns t...
2020-12-09 21:39
1528
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy ...
2020-12-09 21:00
5788
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 311 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 301 media titles]
2025-12-09 13:31
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4378
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3584
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3547
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3234
